Newer mechanism (centanafadine)
1 PRODUCT · CLASS OVERVIEW
Reviewed by Tariq Halim, MD · Last medical review: November 4, 2026 · Editorial policy
This page lists the 1 newer-mechanism product on this site, with the facts each product page cites from its FDA label. Open a product for full details, both patient and clinician views, and sources.
Overview
- Active ingredient: centanafadine.
- DEA schedule: Schedule III controlled substance (CIII); DEA interim final rule effective Oct 30, 2026.
- Generic available: 0 of 1 (see the table; status from each product’s Orange Book data).
- Forms: Extended-release capsule.
- Status notes: Simtriyo: now marketable · check pharmacy availability.
How it works
Centanafadine blocks the reuptake of three brain messengers — norepinephrine, dopamine and serotonin — so more of each stays available between nerve cells.
Mechanism summary reused from the Simtriyo page (mechanism per its Prescribing Information, revised 10/2026).
Products
Formulation, duration and approved ages as stated on each product page (from its label). Generic: “Yes” means an FDA-approved generic or authorized generic is available.
| Product | Formulation | Duration | Approved ages | Generic |
|---|---|---|---|---|
| Simtriyo now marketable · check pharmacy availability | Extended-release capsule | Taken once each morning; the label does not describe when effects start or stop (peak about 5 hours). | Adults, and children 6 years and older weighing at least 20 kg | No |
Comparisons and guides
Sources
Each product’s current prescribing information, as cited on its page (other sources are listed on each product page):
- Otsuka Pharmaceutical Co., Ltd. Simtriyo (centanafadine) extended-release capsules, for oral use, CIII. Prescribing Information, revised 10/2026, accessed Nov 4, 2026. Otsuka.
EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. See the medical disclaimer.